Literature DB >> 10813281

Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists.

K Newhall-Perry1, N J Law, B Ramos, M Sterz, W K Wong, K J Bulpitt, G Park, M Lee, P Clements, H E Paulus.   

Abstract

OBJECTIVE: To examine the direct and indirect costs of rheumatoid arthritis (RA) during the first year of disease.
METHODS: As part of a longitudinal observational study, 150 patients with seropositive RA of 5.9 +/- 2.9 mo duration were recruited through the Western Consortium of Practicing Rheumatologists. Subjects completed questionnaires about health care services and resources utilized and about the number of days of usual activity lost as a result of RA during the 6 month period prior to enrolment.
RESULTS: Study participants had active RA as evidenced by mean tender and swollen joint counts of 24.9 +/- 13.5 and 20.6 +/- 11.6, respectively, and moderate functional impairment reflected by a mean Health Assessment Questionnaire (HAQ) score of 1.24 +/- 0.7. The average total direct cost of RA was $200/month. Health care visits, medications, and radiographs accounted for 78% of the total direct cost, while expenditures for hospitalizations accounted for only 3.5% of the total. The average number of days of usual activity lost per month because of RA was 3.8 +/- 7.7, translating into an average indirect cost of $281/month. Of the 95 subjects who were gainfully employed prior to disease onset, 12 were disabled and 5 were on sick leave as a result of RA, corresponding to a work disability rate of 18%. Work disabled subjects reported significantly lower total household incomes and higher HAQ disability and global disease activity scores than subjects who continued working.
CONCLUSION: In this group of patients with seropositive RA substantial costs, both direct and indirect, were incurred during the first year of disease.

Entities:  

Mesh:

Year:  2000        PMID: 10813281

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

1.  The case for stratified cost-effectiveness analysis by baseline health-related QOL: theory and sensitivity analysis.

Authors:  Joseph Schaafsma
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.

Authors:  K Puolakka; H Kautiainen; M Pekurinen; T Möttönen; P Hannonen; M Korpela; M Hakala; M Arkela-Kautiainen; R Luukkainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2005-11-16       Impact factor: 19.103

5.  Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.

Authors:  Lisa G Suter; Liana Fraenkel; R Scott Braithwaite
Journal:  Arch Intern Med       Date:  2011-04-11

Review 6.  A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings.

Authors:  D P Lubeck
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

7.  Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity.

Authors:  S M M Verstappen; A Boonen; H Verkleij; J W J Bijlsma; E Buskens; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2005-04-28       Impact factor: 19.103

8.  Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.

Authors:  A Boonen; D van der Heijde; R Landewé; A Spoorenberg; H Schouten; M Rutten-van Mölken; F Guillemin; M Dougados; H Mielants; K de Vlam; H van der Tempel; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

9.  Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.

Authors:  A Boonen; D van der Heijde; R Landewé; F Guillemin; M Rutten-van Mölken; M Dougados; H Mielants; K de Vlam; H van der Tempel; S Boesen; A Spoorenberg; H Schouten; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

10.  [Productivity costs of rheumatoid arthritis in Germany. Cost composition and prediction of main cost components].

Authors:  S Merkesdal; J L Huelsemann; T Mittendorf; S Zeh; H Zeidler; J Ruof
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.